• 1
    Van Kerrebroeck P, Abrams P, Chaikin D et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 17983.
  • 2
    Fiske J, Scarpero HM, Xue X, Nitti VW. Degree of bother caused by nocturia in women. Neurourol Urodyn 2004; 23: 1303.
  • 3
    Yu HJ, Chen FY, Huang PC, Chen TH, Chie WC, Liu CY. Impact of nocturia on symptom-specific quality of life among community-dwelling adults aged 40  and older. Urology 2006; 67: 7138.
  • 4
    Appell RA, Sand PK. Nocturia: etiology, diagnosis, and treatment. Neurourol Urodyn 2008; 27: 349.
  • 5
    Abrams PA, Mattiasson A, Van Kerrebroeck P, Robertson G. Is nocturnal polyuria a key factor in nocturia? Neurourol Urodyn 2004; 23: 466.
  • 6
    Swithinbank LV, Vestey S, Abrams P. Nocturnal polyuria in community-dwelling women. BJU Int 2004; 93: 5237.
  • 7
    Rembratt A, Norgaard JP, Andersson KE. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int 2003; 91: 4550.
  • 8
    Bing MH, Moller LA, Jennum P, Mortensen S, Skovgaard LT, Lose G. Prevalence and bother of nocturia, and causes of sleep interruption in a Danish population of men and women aged 60-80 years. BJU Int 2006; 98: 599604.
  • 9
    Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC Study. Eur Urol 2006; 50: 130615.
  • 10
    Chen FY, Dai YT, Liu CK, Yu HJ, Liu CY, Chen TH. Perception of nocturia and medical consulting behavior among community-dwelling women. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 4316.
  • 11
    Rechtschaffen A. The control of sleep. In: HuntWA, ed. Human Behaviour and its Control. Cambridge, MA: Schenkman, 1971: 7592.
  • 12
    Begin M. White Nights: The Story of a Prisoner in Russia. New York: Harper and Row, 1979.
  • 13
    Barnett KJ. The effects of a poor night sleep on mood, cognitive, autonomic and electrophysiological measures. J Integr Neurosci 2008; 7: 40520.
  • 14
    Cote KA, Milner CE, Osip SL, Ray LB, Baxter KD. Waking quantitative electroencephalogram and auditory event-related potentials following experimentally induced sleep fragmentation. Sleep 2003; 26: 68794.
  • 15
    Paunio T, Korhonen T, Hublin C et al. Longitudinal study on poor sleep and life dissatisfaction in a nationwide cohort of twins. Am J Epidemiol 2009; 169: 20613.
  • 16
    Daley M, Morin CM, Leblanc M, Gregoire JP, Savard J, Baillargeon L. Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents. Sleep Med 2009; 10: 42738.
  • 17
    Williamson AM, Feyer AM. Moderate sleep deprivation produces impairments in cognitive and motor performance equivalent to legally prescribed levels of alcohol intoxication. Occup Environ Med 2000; 57: 64955.
  • 18
    Asplund R. Nocturia: consequences for sleep and daytime activities and associated risks. Eur Urol Suppl 2005; 3: 2432.
  • 19
    Lyznicki JM, Doege TC, Davis RM, Williams MA. Sleepiness, driving, and motor vehicle crashes. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279: 190813.
  • 20
    Ferrie JE, Shipley MJ, Cappuccio FP et al. A prospective study of change in sleep duration: associations with mortality in the Whitehall II cohort. Sleep 2007; 30: 165966.
  • 21
    Shirasu-Hiza M, Schneider D. Circadian Rhythm and Immunity in Drosophila: A Model for Neuroimmune Communication. Presented at the American Society for Cell Biology 48th Annual Meeting, San Francisco, CA, 2008. December 13–17.
  • 22
    Toth LA. Sleep, sleep deprivation and infectious disease: studies in animals. Adv Neuroimmunol 1995; 5: 7992.
  • 23
    Opp MR. Sleeping to fuel the immune system: mammalian sleep and resistance to parasites. BMC Evol Biol 2009; 9: 8.
  • 24
    Preston BT, Capellini I, McNamara P, Barton RA, Nunn CL. Parasite resistance and the adaptive significance of sleep. BMC Evol Biol 2009; 9: 7.
  • 25
    Tasali E, Leproult R, Ehrmann DA, Van CE. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA 2008; 105: 10449.
  • 26
    Bliwise DL, Foley DJ, Vitiello MV, Ansari FP, Ancoli-Israel S, Walsh JK. Nocturia and disturbed sleep in the elderly. Sleep Med 2008; 10: 5408.
  • 27
    Middelkoop HA, Smilde-van den Doel DA, Neven AK, Kamphuisen HA, Springer CP. Subjective sleep characteristics of 1,485 males and females aged 50–93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci 1996; 51: M10815.
  • 28
    Van Kerrebroeck PE, Rezapour M, Cortesse A, Thuroff J, Riis A, Norgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur Urol 2007; 52: 2219.
  • 29
    Hernandez FC, Ristol PJ, Estivill E, Batista Miranda JE, Lopez Aramburu MA. Importance of nocturia and its impact on quality of sleep and quality of life in patient with benign prostatic hyperplasia. Actas Urol Esp 2007; 31: 2629.
  • 30
    Ohayon MM. Nocturnal awakenings and comorbid disorders in the American general population. J Psychiatr Res 2008; 43: 4854.
  • 31
    Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003; 91: 1905.
  • 32
    Van Dijk L, Kooij DG, Schellevis FG. Nocturia in the Dutch adult population. BJU Int 2002; 90: 6448.
  • 33
    Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003; 92: 94854.
  • 34
    Mossey JM, Shapiro E. Self-rated health: a predictor of mortality among the elderly. Am J Public Health 1982; 72: 8008.
  • 35
    Taub LF, Redeker NS. Sleep disorders, glucose regulation, and type 2 diabetes. Biol Res Nurs 2008; 9: 23143.
  • 36
    Asplund R. Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch Gerontol Geriatr 2006; 43: 31926.
  • 37
    Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992; 40: 121720.
  • 38
    Asplund R. Nocturia in the elderly in relation to thirst, dry mouth and dry eyes. Can J Urol 2004; 11: 23226.
  • 39
    Asplund R. Nocturnal giddiness in relation to nocturia and other symptoms and to medication in the elderly. Arch Gerontol Geriatr 2005; 40: 10311.
  • 40
    Nakagawa H, Ikeda Y, Niu K et al. Does nocturia increase fall-related fractures and mortality in a community-dwelling elderly population aged 70 years and over? Results of a 3-year prospective cohort study in Japan Neurourol Urodyn 2008; 27: 6745.
  • 41
    Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999; 84: 297301.
  • 42
    Nakagawa H, Ikeda Y, Niu K et al. Association between nocturia and mortality in a community-dwelling elderly population aged 70 years and over: results of a 3-year prospective cohort study in Japan. J Urol 2009; 181: 8.
  • 43
    Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 2008; 101: 13817.
  • 44
    Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 73741.
  • 45
    Drake NL, Flynn MK, Romero AA, Weidner AC, Amundsen CL. Nocturnal polyuria in women with overactive bladder symptoms and nocturia. Am J Obstet Gynecol 2005; 192: 16826.
  • 46
    Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005; 4 (Suppl.): S1219.
  • 47
    Pesce F, Rubilotta E, D’Amico A, Siracusano S, Righetti R, Celia A, et al. Long-Term Anticholinergic Therapy: Duration and Causes of Discontinuation. International Continence Society: Florence, Italy, 2003. Abstract 304.
  • 48
    Chang SC, Lin AT, Chen KK, Chang LS. Multifactorial nature of male nocturia. Urology 2006; 67: 5414.
  • 49
    Yoshimura K, Ohara H, Ichioka K et al. Nocturia and benign prostatic hyperplasia. Urology 2003; 61: 78690.
  • 50
    Johnson TM, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003; 170: 1458.
  • 51
    Djavan B, Milania S, Daviesb J, Bolodeokub J. The impact of Tamsulosin Oral Controlled Absorption System (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 2005; 4: 618.
  • 52
    Yoong HF, Sundaram MB, Aida Z. Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia. Med J Malaysia 2005; 60: 2946.
  • 53
    Weiss J. Prevalence of nocturnal polyuria in nocturia. J Urol 2009; 181: 538.
  • 54
    Schulman C, Asplund R, Desgrandchamps F, Jonas U. The impact of nocturia on health status and quality of life in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 2005; 4: 18.
  • 55
    Kreder KJ, Dmochowski R, Abrams P. The Overactive Bladder: Evaluation and Management. London: Informa Healthcare, 2007.
  • 56
    Rosenberg MT, Staskin DR, Kaplan SA, Macdiarmid SA, Newman DK, Ohl DA. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007; 61: 153546.
  • 57
    Norgaard JP, Hashim H, Malmberg L, Robinson D. Antidiuresis therapy: mechanism of action and clinical implications. Neurourol Urodyn 2007; 26: 100813.
  • 58
    Robertson GL, Norgaard JP. Renal regulation of urine volume: potential implications for nocturia. BJU Int 2002; 90(Suppl 3): 710.
  • 59
    Andersson K, Chapple C, Cardozo L, Cruz F, Hashim H, Michel M, et al. Pharmacological Treatment of Urinary Incontinence. Report from the 4th International Consultation on Incontinence. Paris, France: Health Publications Ltd, 2009.
  • 60
    Rittig S, Jensen AR, Jensen KT, Pedersen EB. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol 1998; 48: 23541.
  • 61
    Vande Walle JG, Bogaert GA, Mattsson S et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 2006; 97: 6039.
  • 62
    Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89: 85562.
  • 63
    Lose G, Lalos O, Freeman RM, Van Kerrebroeck P. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003; 189: 110613.
  • 64
    Lose G, Mattiasson A, Walter S et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004; 172: 10215.
  • 65
    Vande Walle J, Stockner M, Raes A, Norgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007; 2: 2328.
  • 66
    Tikkinen KA, Johnson TM, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 2009; 57: 48896.
  • 67
    Asplund R, Aberg H. Nocturnal micturition, sleep and well-being in women of ages 40–64 years. Maturitas 1996; 24: 7381.
  • 68
    Holm-Larsen T, Sorensen J, Hansen EH, Norgaard JP. Desmopressin is more cost effective than behavioural treatment in adults suffering from nocturia when applying a societal perspective. J Urol 2008; 179: 56.
  • 69
    McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 238798.
  • 70
    Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 61621.
  • 71
    Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006; 68: 32832.